Public Release:  Thiopurine therapy improves quality of life

BioMed Central

Patients with inflammatory bowel diseases (IBDs) such as Crohn's disease or ulcerative colitis do perceive a benefit from thiopurine treatment. A report in the open access journal BMC Gastroenterology has demonstrated improved health-related quality of life in 92 IBD patients.

Guillermo Bastida worked with a team of researchers from La Fe Hospital, Valencia, Spain, to investigate the controversial thiopurine treatment. He said, "The efficacy of thiopurines in the scenarios in which they are prescribed, either to induce or to maintain remission in IBD, is well proven. Their effect on quality of life has been a cause for concern however, with some reports suggesting that they can cause patients to perceive their lives as being more difficult while under treatment. However, the available data were scarce, so we carried out this clinical trial to study the problem more closely".

Bastida and his colleagues report that after one year of treatment with thiopurines, quality of life had improved significantly compared with baseline and all the scores were higher than those obtained at six months.

###

Media Contact
Graeme Baldwin
Press Office, BioMed Central
Tel: +44 (0) 20 3192 2165
Mob: +44 (0) 7825 706422
Email: graeme.baldwin@biomedcentral.com

Notes to Editors

1. The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients
Guillermo Bastida, Pilar Nos, Mariam Aguas, Marisa Iborra, Vicente Ortiz, Vicente Garrigues and Julio Ponce
BMC Gastroenterology (in press)

During embargo, article available here After the embargo, article available at journal website

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Article citation and URL available on request at press@biomedcentral.com on the day of publication

2. BMC Gastroenterology is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of gastrointestinal and hepatobiliary disorders, as well as related molecular genetics, pathophysiology, and epidemiology. BMC Gastroenterology (ISSN 1471-230X) is indexed/tracked/covered by PubMed, MEDLINE, CAS, EMBASE, Scopus, Current Contents, Thomson Reuters (ISI) and Google Scholar.

3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.